Nudge
Nudge is a biotechnology company developing the Nudge Zero helmet, a non-invasive brain interface using focused ultrasound for precise neuromodulation.
Secondary Market Price
Secondary Market Price
How Nudge Measures Up
To help you manage your Nudge equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We are still gathering data to complete our evaluation of Nudge. Check back soon for our rating on the company's projected worth in four years.
Exit Risk
TBD
We are still gathering data on Nudge to train our machine learning model. Check back soon for our exit risk rating for Nudge!
Funding Stage
Series A
Nudge's Series A funding shows they have a solid foundation and are now focused on serious growth. This means you'd be joining at a pivotal moment, with a chance to make a real impact as the company expands.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Nudge's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Nudge Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Nudge's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Nudge is a biotechnology research company developing non-invasive brain interfaces that use focused ultrasound to both stimulate and image neural circuits. The company's technology is being built into helmet-style devices, such as its first system called Nudge Zero, which is a high channel count, ultrasound phased array designed for use in an MRI. This platform aims to treat neurological and psychiatric disorders like addiction, chronic pain, essential tremor, and PTSD by targeting millimeter-scale regions of the brain without surgery. Founded in San Francisco in 2024 by a team with experience in neuromodulation, Nudge developed and began using its Nudge Zero system in human research studies within months of its inception.
The company has recently gained significant momentum, announcing a $100 million Series A funding round led by Thrive Capital and Greenoaks. This investment supports its growth to a team of over 25 people and its active hiring across multiple technical and operational roles. Nudge's long-term plan involves a four-step process: first, proving the neuromodulatory effect of ultrasound; second, demonstrating its beneficial effects in treating specific conditions; third, creating a scalable device; and finally, developing a generalized device. The ultimate goal is to make its brain interface technology widely accessible for both therapeutic applications and the enhancement of human experience.
- Founders Fund
- Khosla Ventures
- SVA
- Abstract Ventures
- Valor Equity Partners
- Peter Thiel
- Co-Founder, CEO Fred Ehrsam
- Co-Founder, CTO Jeremy Barenholtz
- Co-Founder, Quintin Frerichs
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Nudge worth joining?
Evaluating if a startup like Nudge is worth joining requires analyzing its growth potential and the value of its equity compensation. Platforms like Prospect can help by providing data-driven insights and projections on startup equity, similar to what venture capitalists use.
What should I do with my Nudge stock?
Managing your Nudge stock involves making strategic decisions about when to exercise options or sell shares to maximize your post-tax returns. Using an equity management platform like Prospect can help you model different scenarios and create an optimized strategy.
Can you sell Nudge stock?
As Nudge is a private company, selling its stock is more complex than selling shares of a publicly-traded company and typically depends on company policies or secondary market availability. Tools like Prospect can provide insights into secondary market prices and help you navigate the process of selling private shares.
How can I find the value of my Nudge stock?
The value of stock in a private company like Nudge isn't publicly listed and is typically based on its last 409A valuation or recent secondary market transactions. You can use a platform like Prospect, which uses VC-grade data and models to provide an independent projection of what your equity is likely worth.
What is Nudge's equity worth?
The precise worth of Nudge's equity depends on factors like its latest valuation, growth metrics, and overall market conditions. To get a reliable estimate, you can use tools like Prospect which analyze these data points to project the potential value of your holdings.
What is Nudge's stock ticker symbol?
Since Nudge is a private company and not traded on a public stock exchange, it does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Nudge stock?
Buying stock in a private company like Nudge is typically limited to accredited investors or employees, while selling often occurs through secondary markets or company-tendered offers. Platforms such as Prospect can offer visibility into secondary market pricing and help you plan for selling events.
What is the criteria to buy or invest in Nudge stock?
Investing in a private company like Nudge is generally restricted to employees receiving equity compensation or accredited investors who meet specific income or net worth requirements. These opportunities typically arise during funding rounds or through transactions on secondary markets.
